Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

anti-infectives

- PMLiVE

Merck KGaA exec takes top job at UK biotech Kymab

UK biotech veteran returns to head antibody specialist

- PMLiVE

Investments show UK biotech still booming despite Brexit

UK raised a quarter of all European biotech funds

- PMLiVE

Novartis and Syncona back new Swiss biotech Anaveon

Founders focused on IL-2 Receptor Agonists

- PMLiVE

Ex-Pharmacyclics CEO invests $25m in Summit

After Duchenne drug failure, UK biotech looks to new anti-infective

- PMLiVE

MedCity sets up advanced therapy research network

Aims to capitalise on UK's expertise in cutting-edge field

- PMLiVE

New leader at Medivir after setbacks

Christine Lind departs Swedish biotech

- PMLiVE

Orchard plans IPO as gene therapy pipeline advances

UK biotech seeks funds for expanded rare disease portfolio

- PMLiVE

Daily Brief: Summit’s $12m lifeline, Biohaven’s speech anxiety pill, Crescendo’s Humabody progress

News from pharma, biotech and healthcare

- PMLiVE

DNA damage specialists Artios Pharma raises $84m

Team behind development of Lynparza focus on next-gen DDR inhibitors

- PMLiVE

Vernalis accepts £33m takeover offer from Ligand Pharma

Biotech buyout brings team of 70 scientists in Cambridge, UK

- PMLiVE

Abingworth raises $315m to expand hunt for promising biotechs

New fund earmarked for early to late-stage European and US firms

- PMLiVE

Sanofi’s rare blood disorder drug Cablivi set for European approval

Rare disease drug among notable CHMP recommendations

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links